NCT01872819View on ClinicalTrials.gov

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 2, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 17, 2014

Conditions
Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiablePreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaRefractory Anemia With Excess Blasts
Interventions
OTHER

antitumor drug screening assay

Undergo high throughput drug sensitivity assay

DRUG

chemotherapy

Patients receive 1 of 160 possible interventions

BIOLOGICAL

biological therapy

Patients receive 1 of 160 possible interventions

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT01872819 - Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay | Biotech Hunter | Biotech Hunter